Cancer chemopreventionprogress and promise

European Journal of Cancer

Volumn 35, Issue 14, 1999, Pages 2031-2038

  Kelloff, G J ^a   Sigman, C C ^b   Greenwald, P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CCS Associates   (United States)

Author keywords

Chemoprevention; Intra epithelial neoplasia; Molecular carcinogenesis; Risk evaluation; Surrogate endpoints

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BICALUTAMIDE; BUDESONIDE; CARCINOGEN; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; DIMETHYLHYDRAZINE; EFLORNITHINE; EPIGALLOCATECHIN GALLATE; EXEMESTANE; FLUTAMIDE; FOLIC ACID; GENISTEIN; ISOFLAVONE; ISOFLAVONE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OLTIPRAZ; PIROXICAM; PROTEINASE INHIBITOR; RETINOID; SELENIUM; STEROID; SULINDAC; TAMOXIFEN; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VOROZOLE; TUMOR MARKER;

CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; DIET; DRUG DEVELOPMENT; HEALTH PROMOTION; HUMAN; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; DRUG DESIGN; HEALTH EDUCATION; NEOPLASM; RISK FACTOR;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HEALTH EDUCATION; HUMANS; NEOPLASMS; PUBLIC HEALTH; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033233393     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00299-3     Document Type: Article

References (41)

1. Kelloff G.J., Hawk E.T., Crowell J.A.et al. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology (Huntington). 10:1996;1471-1480. 1484.
2. Kelloff G.J., Hawk E.T., Karp J.E.et al. Progress in clinical chemoprevention. Semin. Oncol. 24:1997;241-252.
3. Hong W.K., Sporn M.B. Recent advances in chemoprevention of cancer. Science. 278:1997;1073-1077.
4. Kelloff G.J. Perspectives on cancer chemoprevention research and drug development. Advances Cancer Res. 78:1999;199-334.
5. Henderson B.E., Ross R., Bernstein L. Oestrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 48:1988;246-253.
6. Ross R.K., Pike M.C., Coetzee G.A.et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 58:1998;4497-4504.
7. Miller M.S., McCarver D.G., Bell D.A., Easton D.L., Goldstein J.A. Genetic polymorphisms in human drug metabolic enzymes. Fundamental Appl. Toxicol. 40:1997;1-14.
8. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
9. Califano J., van der Riet P., Westra W.et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 56:1996;2488-2492.
10. Kelloff GJ, Boone CW, Steele VE, et al. Mechanistic considerations in chemopreventive drug development. J Cell Biochem 1994, (Suppl. 20), 1-24.
11. Fisher B., Costantino J.P., Wickerham D.L.et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90:1998;1371-1388.
12. Heinonen O.P., Albanes D., Virtamo J.et al. Prostate cancer and supplementation with α-tocopherol and β-carotene: incidence and mortality in a controlled trial. J. Natl. Cancer Inst. 90:1998;440-446.
13. Kelloff G.J., Johnson J.J., Crowell J.A.et al. Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol. Biomarkers Prevent. 4:1995;1-10.
14. Sporn M.B. The war on cancer. Lancet. 347:1996;1377-1381.
15. Schipper H., Turley E.A., Baum M. A new biological framework for cancer research. Lancet. 348:1996;1149-1151.
16. Sidransky D., Mikkelsen T., Schwechheimer K.et al. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature. 355:1992;846-847.
17. Sidransky D., Messing E. Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumour suppressor genes, and growth factors. Urol. Clin. N. Am. 19:1992;629-639.
18. Sidransky D., Frost P., Von Eschenbach A.et al. Clonal origin of bladder cancer. N. Engl. J. Med. 326:1992;737-740.
19. Rosin M.P., Cairns P., Epstein J.I.et al. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res. 55:1995;5213-5216.
20. Mao L., Schoenberg M.P., Scicchitano M.et al. Detection of primary bladder cancer by microsatellite analysis. Science. 271:1996;659-662.
21. Simoneau A.R., Jones P.A. Bladder cancer: the molecular progression to invasive disease. World J. Urol. 12:1994;89-95.
22. Thiberville L., Payne P., Vielkinds J.et al. Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res. 55:1995;5133-5139.
23. Kishimoto Y., Sugio K., Hung J.Y.et al. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J. Natl. Cancer Inst. 87:1995;1224-1229.
24. Larson A.A., Liao S.-Y., Stanbridge E.J.et al. Genetic alterations accumulate during cervical tumorigenesis and indicate a common origin for multifocal lesions. Cancer Res. 57:1997;4171-4176.
25. Brown P.O., Botstein D. Exploring the new world of the genome with DNA microarrays. Nature Genet. 21(Suppl.):1999;33-37.
26. Sneige N., Lagios M.D., Schwarting R.et al. Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ. Human Pathol. 30:1999;257-262.
27. Su L.-K., Kinzler K.W., Vogelstein B.et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 256:1992;668-670.
28. Edelmann W., Yang K., Kuraguchi M.et al. Tumorigenesis in MLH1 and MLH1/Apc1638N mutant mice. Cancer Res. 59:1999;1301-1307.
29. Jacoby R.F., Marshall D.J., Newton M.A.et al. Chemoprevention of spontaneous intestinal adenomas in the ApcMin mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. 56:1996;710-714.
30. Arbeit J.M., Howley P.M., Hanahan D. Chronic oestrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc. Natl. Acad. Sci. USA. 93:1996;2930-2935.
31. Matzinger S.A., Crist K.A., Stoner G.D.et al. K-ras mutations in lung tumours from A/J and A/J X TSG-p53 F1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate. Carcinogenesis. 16:1995;2487-2492.
32. Wattenberg L.W., Wiedmann T.S., Estensen R.D.et al. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res. 57:1997;5489-5492.
33. Reddy B.S., Nayini J., Tokumo K.et al. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res. 50:1990;2562-2568.
34. Anzano M.A., Byers S.W., Smith J.M.et al. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 54:1994;4614-4617.
35. Anzano M.A., Peer C.W., Smith J.M.et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J. Natl. Cancer Inst. 88:1990;123-125.
36. Lucia M.S., Anzano M.A., Slayter M.V.et al. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res. 55:1995;5621-5627.
37. Westra W.H., Sidransky D. Phenotypic and genotypic disparity in premalignant lesions: of calm water and crocodiles. J. Natl. Cancer Inst. 90:1998;1500-1501.
38. Mao L., El-Naggar A.K., Papadimitrakopoulou V.et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J. Natl. Cancer Inst. 90:1998;1545-1551.
39. Hittelman WN, Kim HJ, Lee JS, et al. Detection of chromosome instability of tissue fields at risk: in situ hybridization. J Cell Biochem 1996, (Suppl. 25), 57-62.
40. Boone C.W., Bacus J.W., Bacus J.V.et al. Properties of intraepithelial neoplasia relevant to cancer prevention and to the development of surrogate endpoints for clinical trials. Proc. Soc. Exp. Med. Biol. 216:1997;151-166.
41. Kelloff G.J., Lieberman R.L., Steele V.E.et al. Chemoprevention of prostate cancer: concepts and strategies. Eur. J. Urol. 35:1999;342-350.